Evolutionary Genomics Stock Cash Flow From Operations
| FNAM Stock | USD 0.0002 0.00 0.00% |
Fundamental analysis of Evolutionary Genomics allows traders to better anticipate movements in Evolutionary Genomics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Evolutionary |
Evolutionary Genomics Company Cash Flow From Operations Analysis
Evolutionary Genomics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Evolutionary Genomics Cash Flow From Operations | (1.58 M) |
Most of Evolutionary Genomics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evolutionary Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Evolutionary Genomics has (1.58 Million) in Cash Flow From Operations. This is 100.3% lower than that of the Healthcare sector and 102.53% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.16% higher than that of the company.
Evolutionary Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolutionary Genomics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evolutionary Genomics could also be used in its relative valuation, which is a method of valuing Evolutionary Genomics by comparing valuation metrics of similar companies.Evolutionary Genomics is currently under evaluation in cash flow from operations category among its peers.
Evolutionary Fundamentals
| Return On Equity | -145.27 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 9.18 M | |||
| Shares Outstanding | 6.66 M | |||
| Shares Owned By Insiders | 32.60 % | |||
| Price To Earning | (3.79) X | |||
| Price To Sales | 352.91 X | |||
| Gross Profit | (1.23 M) | |||
| EBITDA | (1.84 M) | |||
| Net Income | (2.79 M) | |||
| Cash And Equivalents | 897.78 K | |||
| Cash Per Share | 0.14 X | |||
| Total Debt | 3.74 M | |||
| Debt To Equity | 1.81 % | |||
| Current Ratio | 9.85 X | |||
| Book Value Per Share | (1.05) X | |||
| Cash Flow From Operations | (1.58 M) | |||
| Earnings Per Share | (0.53) X | |||
| Beta | -0.0153 | |||
| Market Capitalization | 4.66 M | |||
| Total Asset | 2.93 M | |||
| Retained Earnings | (1.33 M) | |||
| Working Capital | (12.68 K) | |||
| Current Asset | 991 | |||
| Current Liabilities | 13.67 K | |||
| Z Score | 0.6 | |||
| Net Asset | 2.93 M |
About Evolutionary Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evolutionary Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolutionary Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolutionary Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.